RLYB (rallybio.com) Future Price to Earnings

Official company branding of Rallybio (RLYB)

Rallybio Corporation (RLYB) is betting on the internal growth of orphan drug development without mergers, which has triggered momentum in the company's current forward P/E. The mark 0.00 serves as the current indicator for this metric. High authority in neonatal rescue supports the share price, however, geopolitical disruptions in biomaterial logistics create serious risks for the global implementation of new drugs.

Rallybio Corporation - RLYB Market Cap to Future Earnings Ratio (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for rallybio.com (RLYB)

- current price and projected stock value:
- business market valuation indicators:
Fundamental valuation:RLYB Rallybio Corporation
Brand item of Rallybio Corporation

The forward P/E compares the current market value of a share with current consensus earnings forecasts, allowing for a real-time assessment of whether an asset is fundamentally overbought or undervalued. By analyzing the projected P/E of Rallybio Corporation (RLYB) on GURU.Markets, an investor can distinguish market noise from actual value growth for Rallybio Corporation (RLYB), given that patent protection for orphan drugs guarantees high margins upon the successful completion of clinical trials.

Direct competitors

Future Price to Earnings haleon.com (HLN)|KVUE (Kenvue Health) - Future Price to Earnings Multiple|Future Price to Earnings Verona Pharma PLC VRNA|Jyong Biotech (MENS) - Projected Price to Earnings Ratio|LGND: Projected Price to Earnings|Amneal - Market Cap to Future Earnings Ratio|PRGO: Forward P/E Multiple|Alvotech Corp - Future Price to Earnings Multiple|LQDA (Liquidia Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio glpg.com GLPG|Future Price to Earnings ANI Pharmaceuticals, Inc. (ANIP)|MNKD (MannKind Corp) - Future Price to Earnings Multiple|Forward P/E Multiple AMPH (Amphastar Pharmaceuticals Inc)|PCRX (Pacira) - Price to Expected Earnings Ratio|SPRY - Future Price to Earnings|Future Price to Earnings Multiple TBPH (Theravance Biopharma)|AQST (aquestive.com) - Projected Price to Earnings|Price to Expected Earnings Ratio SCPH (scPharmaceuticals, Inc.)|Projected Price to Earnings TECX|Tonix Pharmaceuticals (TNXP) - Market Cap to Projected Earnings|Forward P/E Multiple SXTC|Forward P/E Multiple Eupraxia Pharma (EPRX)|Future Price to Earnings BioHarvest Sciences Inc. BHST|EXOZ - Projected Price to Earnings|ORMP: Projected Price to Earnings|Future Price to Earnings Multiple ENTX (enterabio.com)|MindWalk Therapeutics (HYFT) - Future Price to Earnings|Projected Price to Earnings Ratio abvcpharma.com (ABVC)|Future Price to Earnings Cumberland Pharma|Future Price to Earnings QNTM|Forward P/E Multiple FGEN|TELO (Telomir Pharma) - Future Price to Earnings Multiple|Future Price to Earnings Rani Therapeutics Holdings RANI|SNYR - Projected Price to Earnings|LEXX - Future Price to Earnings|PULM (Pulmatrix) - Price to Future Earnings Ratio|Pheton Holdings Ltd (PTHL) - Future Price to Earnings|Aptorum - Future Price to Earnings Multiple|Projected Price to Earnings LYRA|Projected Price to Earnings Impact BioMedical Inc (IBO)|Forward P/E Multiple TNFA|YCBD: Price to Expected Earnings Ratio|Future Price to Earnings PainReform PRFX|altamiratherapeutics.com (CYTO) - Projected Price to Earnings Ratio|LIPO: Projected Price to Earnings|OPTN (optinose.com) - Price to Future Earnings Ratio|PIRS: Forward P/E Multiple|PROC - Market Cap to Projected Earnings|PTPI (Petros Pharma) - Forward P/E Multiple|Future Price to Earnings QLI|Forward P/E Multiple SLRN|Market Cap to Future Earnings Ratio TFFP